Skip to content

Bristol Myers Squibb Co

NYSE: BMY · USD

Bristol Myers Squibb Co revenue81

Quarterly and annual revenue from company filings.

Business drivers

Business lines and operating measures.

Eliquis revenue

Reported quarterly Eliquis revenue. Quarterly figures · USD

Eliquis revenue. Reported quarterly Eliquis revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 30, 2026From Apr 1, 20264,481,000,000Filed Jul 30, 2026
Mar 31, 2026From Jan 1, 20264,137,000,000Filed Apr 30, 2026
Jun 30, 2025From Apr 1, 20253,680,000,000Filed Jul 30, 2026
Mar 31, 2025From Jan 1, 20253,565,000,000Filed Apr 30, 2026

Opdivo revenue

Reported quarterly Opdivo revenue. Quarterly figures · USD

Opdivo revenue. Reported quarterly Opdivo revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 30, 2026From Apr 1, 20262,485,000,000Filed Jul 30, 2026
Mar 31, 2026From Jan 1, 20262,146,000,000Filed Apr 30, 2026
Jun 30, 2025From Apr 1, 20252,560,000,000Filed Jul 30, 2026
Mar 31, 2025From Jan 1, 20252,265,000,000Filed Apr 30, 2026

Reblozyl revenue

Reported quarterly Reblozyl revenue. Quarterly figures · USD

Reblozyl revenue. Reported quarterly Reblozyl revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 30, 2026From Apr 1, 2026735,000,000Filed Jul 30, 2026
Mar 31, 2026From Jan 1, 2026555,000,000Filed Apr 30, 2026
Jun 30, 2025From Apr 1, 2025568,000,000Filed Jul 30, 2026
Mar 31, 2025From Jan 1, 2025478,000,000Filed Apr 30, 2026

Independent series; they may overlap and do not form an additive breakdown.

  • The supplied observations provide a short, discontinuous history and measure revenue rather than operating volumes.

Products & projects

Breyanzi

The following are the developments in our marketed products and our late-stage pipeline since the start of the second quarter of 2026 as of July 30, 2026: Product Indication Date Developments Breyanzi MCL & MZL April 2026 Japan's Ministry of Health Labour and Welfare approval of Breyanzi for the treatment of both relapsed or refractory MCL and relapsed or refractory MZL.

Filed · source for Breyanzi

Revenue history

USD millions · Fiscal periods
Jun 30, 2009 through Jun 30, 2026

Quarterly data

Bristol Myers Squibb Co quarterly financial data in USD millions. FY denotes the company's fiscal year. YTD covers reported quarters only.
Fiscal quarterEndedTotal revenueUSD millions
FY 2026 Q2Jun 30, 202612,973, +12.9% versus FY 2026 Q1
FY 2026 Q1Mar 31, 202611,489, −8.1% versus FY 2025 Q4
FY 2025 Q4Dec 31, 202512,502, +2.3% versus FY 2025 Q3
FY 2025 Q3Sep 30, 202512,222, −0.4% versus FY 2025 Q2
FY 2025 Q2Jun 30, 202512,269, +9.5% versus FY 2025 Q1
FY 2025 Q1Mar 31, 202511,201, −9.2% versus FY 2024 Q4
FY 2024 Q4Dec 31, 202412,342, +3.8% versus FY 2024 Q3
FY 2024 Q3Sep 30, 202411,892, −2.5% versus FY 2024 Q2
FY 2024 Q2Jun 30, 202412,201, +2.8% versus FY 2024 Q1
FY 2024 Q1Mar 31, 202411,865, +3.4% versus FY 2023 Q4
FY 2023 Q4Dec 31, 202311,477, +4.7% versus FY 2023 Q3
FY 2023 Q3Sep 30, 202310,966, −2.3% versus FY 2023 Q2
FY 2023 Q2Jun 30, 202311,226, −1.0% versus FY 2023 Q1
FY 2023 Q1Mar 31, 202311,337, −0.6% versus FY 2022 Q4
FY 2022 Q4Dec 31, 202211,406, +1.7% versus FY 2022 Q3
FY 2022 Q3Sep 30, 202211,218, −5.6% versus FY 2022 Q2
FY 2022 Q2Jun 30, 202211,887, +2.1% versus FY 2022 Q1
FY 2022 Q1Mar 31, 202211,648, −2.8% versus FY 2021 Q4
FY 2021 Q4Dec 31, 202111,985, +3.1% versus FY 2021 Q3
FY 2021 Q3Sep 30, 202111,624, −0.7% versus FY 2021 Q2
FY 2021 Q2Jun 30, 202111,703, +5.7% versus FY 2021 Q1
FY 2021 Q1Mar 31, 202111,073, 0.0% versus FY 2020 Q4
FY 2020 Q4Dec 31, 202011,068, +5.0% versus FY 2020 Q3
FY 2020 Q3Sep 30, 202010,540, +4.1% versus FY 2020 Q2
FY 2020 Q2Jun 30, 202010,129, −6.0% versus FY 2020 Q1
FY 2020 Q1Mar 31, 202010,781, +35.7% versus FY 2019 Q4
FY 2019 Q4Dec 31, 20197,945, +32.3% versus FY 2019 Q3
FY 2019 Q3Sep 30, 20196,007, −4.2% versus FY 2019 Q2
FY 2019 Q2Jun 30, 20196,273, +6.0% versus FY 2019 Q1
FY 2019 Q1Mar 31, 20195,920, −0.9% versus FY 2018 Q4
FY 2018 Q4Dec 31, 20185,973, +5.0% versus FY 2018 Q3
FY 2018 Q3Sep 30, 20185,691, −0.2% versus FY 2018 Q2
FY 2018 Q2Jun 30, 20185,704, +9.8% versus FY 2018 Q1
FY 2018 Q1Mar 31, 20185,193, −4.7% versus FY 2017 Q4
FY 2017 Q4Dec 31, 20175,449, +3.7% versus FY 2017 Q3
FY 2017 Q3Sep 30, 20175,254, +2.1% versus FY 2017 Q2
FY 2017 Q2Jun 30, 20175,144, +4.4% versus FY 2017 Q1
FY 2017 Q1Mar 31, 20174,929, −6.0% versus FY 2016 Q4
FY 2016 Q4Dec 31, 20165,243, +6.5% versus FY 2016 Q3
FY 2016 Q3Sep 30, 20164,922, +1.0% versus FY 2016 Q2
FY 2016 Q2Jun 30, 20164,871, +10.9% versus FY 2016 Q1
FY 2016 Q1Mar 31, 20164,391, +2.4% versus FY 2015 Q4
FY 2015 Q4Dec 31, 20154,287, +5.4% versus FY 2015 Q3
FY 2015 Q3Sep 30, 20154,069, −2.3% versus FY 2015 Q2
FY 2015 Q2Jun 30, 20154,163, +3.0% versus FY 2015 Q1
FY 2015 Q1Mar 31, 20154,041, −5.1% versus FY 2014 Q4
FY 2014 Q4Dec 31, 20144,258, +8.6% versus FY 2014 Q3
FY 2014 Q3Sep 30, 20143,921, +0.8% versus FY 2014 Q2
FY 2014 Q2Jun 30, 20143,889, +2.0% versus FY 2014 Q1
FY 2014 Q1Mar 31, 20143,811, −14.2% versus FY 2013 Q4
FY 2013 Q4Dec 31, 20134,441, +9.2% versus FY 2013 Q3
FY 2013 Q3Sep 30, 20134,065, +0.4% versus FY 2013 Q2
FY 2013 Q2Jun 30, 20134,048, +5.7% versus FY 2013 Q1
FY 2013 Q1Mar 31, 20133,831, −8.6% versus FY 2012 Q4
FY 2012 Q4Dec 31, 20124,191, +12.2% versus FY 2012 Q3
FY 2012 Q3Sep 30, 20123,736, −15.9% versus FY 2012 Q2
FY 2012 Q2Jun 30, 20124,443, −15.4% versus FY 2012 Q1
FY 2012 Q1Mar 31, 20125,251, −3.7% versus FY 2011 Q4
FY 2011 Q4Dec 31, 20115,454, +2.0% versus FY 2011 Q3
FY 2011 Q3Sep 30, 20115,345, −1.6% versus FY 2011 Q2
FY 2011 Q2Jun 30, 20115,434, +8.4% versus FY 2011 Q1
FY 2011 Q1Mar 31, 20115,011, −2.0% versus FY 2010 Q4
FY 2010 Q4Dec 31, 20105,111, +6.5% versus FY 2010 Q3
FY 2010 Q3Sep 30, 20104,798, +0.6% versus FY 2010 Q2
FY 2010 Q2Jun 30, 20104,768, −0.8% versus FY 2010 Q1
FY 2010 Q1Mar 31, 20104,807, −4.5% versus FY 2009 Q4
FY 2009 Q4Dec 31, 20095,033, −8.3% versus FY 2009 Q3
FY 2009 Q3Sep 30, 20095,487, +1.9% versus FY 2009 Q2
FY 2009 Q2Jun 30, 20095,384, Change unavailable versus FY 2009 Q1
Sources and definitions

Figures from official company filings and financial reports, in the reported currency. FY identifies the fiscal year; the end date identifies the calendar period. Last checked Oct 19, 2026.

Annual values come from annual filings. Historical quarters retain their reporting basis; rounding and reclassifications can make their sum differ from the annual figure. YTD sums the available fiscal quarters and compares the same quarters of the previous fiscal year.

Missing values are shown as unavailable. Fourth quarters use reported values where available, otherwise the annual amount less the matching nine-month amount.

Total revenue
Reported consolidated revenue from the issuer filing. Each observation identifies its accounting concept; bank net revenue is net of interest expense when that concept is reported.